Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases

Anti‐angiogenic therapies using biological molecules that neutralize vascular endothelial growth factor‐A (VEGF‐A) have revolutionized treatment of retinal vascular diseases including age‐related macular degeneration (AMD). This study reports preclinical assessment of a strategy to enhance anti‐VEGF...

Descripción completa

Detalles Bibliográficos
Autores principales: Regula, Jörg T, Lundh von Leithner, Peter, Foxton, Richard, Barathi, Veluchamy A, Cheung, Chui Ming Gemmy, Bo Tun, Sai Bo, Wey, Yeo Sia, Iwata, Daiju, Dostalek, Miroslav, Moelleken, Jörg, Stubenrauch, Kay G, Nogoceke, Everson, Widmer, Gabriella, Strassburger, Pamela, Koss, Michael J, Klein, Christian, Shima, David T, Hartmann, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5090659/
https://www.ncbi.nlm.nih.gov/pubmed/27742718
http://dx.doi.org/10.15252/emmm.201505889

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5090659/
https://www.ncbi.nlm.nih.gov/pubmed/27742718
http://dx.doi.org/10.15252/emmm.201505889

Ejemplares similares